Karolinska Development AB (publ): Karolinska Development s portfolio company Forendo Pharma advances FOR-6219 to Phase 2 based on positive Phase 1 data
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Investegate |Karolinska Development AB (pub Announcements | Karolinska Development AB (pub: Karolinska Development s portfolio company Forendo Pharma advances FOR-6219 to Phase 2 based on positive Phase 1 data
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Forendo Pharma Successfully Completes Phase 1 Studies of FOR-6219 in Endometriosis, Aiming to Advance Program into Phase 2 Clinical Studies
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
Nachricht vom 14.12.2020 | 06:30
Sensirion Holding AG: Forecast for full-year 2020 raised based on stronger than expected COVID-19 related business
Sensirion Holding AG / Key word(s): Change in Forecast
14-Dec-2020 / 06:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
Media Release
Sensirion: Forecast for full-year 2020 raised based on stronger than expected COVID-19 related business
Sensirion raises its forecast for the financial year 2020. As a result of continuing high demand for gas flow sensors in connection with the COVID-19 pandemic the sensor manufacturer expects now revenue for the full year of approximately CHF 254 million and an adjusted EBITDA margin in the mid-twenties percentage range.